×

Novo Nordisk A/S : Novo Nordisk discontinues its activities within inflammatory disorders

BAGSVAERD, Denmark, Sept. 2, 2014 (GLOBE NEWSWIRE) -- Novo Nordisk today announced a decision to discontinue all its research and development (R&D) activities within inflammatory disorders while increasing its efforts within diabetes prevention and treatment, obesity and diabetes complications.

For further information

Media:
Mike Rulis +45 3079 3573 mike@novonordisk.com
Ken Inchausti (US) +1 609 514 8316 kiau@novonordisk.com
Investors:
Kasper Roseeuw Poulsen +45 3079 4303 krop@novonordisk.com
Jannick Lindegaard Denholt +45 3079 8519 jlis@novonordisk.com
Daniel Bohsen +45 3079 6376 dabo@novonordisk.com
Frank Daniel Mersebach (US) +1 609 786 4575 fdni@novonordisk.com

Company announcement No 53 / 2014

Company announcement No 53 2014 http://hugin.info/2013/R/1852917/647755.pdf

HUG#1852917

Source:Novo Nordisk A/S